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Abstract
Background: Patients with advanced ovarian cancer should be treated by radical debulking surgery aiming
at complete tumor resection. Unfortunately about 70% of the patients present with advanced disease,
when optimal debulking can not be obtained, and therefore these patients gain little benefit from surgery.
Neoadjuvant chemotherapy (NACT) has been proposed as a novel therapeutic approach in such cases. In
this study, we report our results with primary surgery or neoadjuvant chemotherapy as treatment
modalities in the specific indication of operable patients with advanced ovarian carcinoma (no medical
contraindication to debulking surgery).
Patients and methods: A total of 59 patients with stage III or IV epithelial ovarian carcinomas were
evaluated between 1998 and 2003. All patients were submitted to surgical exploration aiming to evaluate
tumor resectability. Neoadjuvant chemotherapy was given (in 27 patients) where optimal cytoreduction
was not feasible. Conversely primary debulking surgery was performed when we considered that optimal
cytoreduction could be achieved by the standard surgery (32 patients).
Results: Optimal cytoreduction was higher in the NACT group (72.2%) than the conventional group
(62.4%), though not statistically significant (P = 0.5). More important was the finding that parameters of
surgical aggressiveness (blood loss rates, ICU stay and total hospital stay) were significantly lower in NACT
group than the conventional group. The median overall survival time was 28 months in the conventional
group and 25 months in NACT group with a P value of 0.5. The median disease free survival was 19 months
in the conventional group and 21 months in NACT group (P = 0.4). In multivariate analysis, the pathologic
type and degree of debulking were found to affect the disease free survival significantly. Overall survival
was not affected by any of the study parameters.
Conclusion: Primary chemotherapy followed by interval debulking surgery in select group of patients
doesn't appear to worsen the prognosis, but it permits a less aggressive surgery to be performed.
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The diagnosis and management of ovarian cancer is one
of the greatest challenges in oncology. Approximately,
half of ovarian carcinoma patients die from the disease
making it the leading cause of gynecologic cancer-related
death in most industrialized countries [1].
Although our approach and knowledge of epithelial ovar-
ian cancer has changed in the past 25 years, the overall
survival has not been affected as approximately 65%
to70% of all cases continue to be diagnosed with stage III
or stage IV disease. Surgical reduction of tumor bulk has
become the preferred first step in the management of
advanced epithelial ovarian cancer [2]. Observations that
the excision of large tumor masses could provide pallia-
tion and a modest extension of life have been recorded for
more than 50 years. Enhancement of sensitivity to chem-
otherapy, yet unproven, could be the greatest benefit of
tumor debulking [3].
Approximately 70% of patients present with advanced
ovarian cancer, when optimal debulking can not be
obtained, and therefore gain little benefit from surgery
[4]. On the other hand, patients who are severely compro-
mised medically carry an unwarranted risk to surgery.
Neoadjuvant chemotherapy (NACT) has been proposed
as a novel therapeutic approach to a variety of solid
tumors when the disease is not amenable to surgical resec-
tion at the time of diagnosis or the patient is unfit for
aggressive debulking surgery [5]. NACT has now been rec-
ognized as a useful modality for the treatment of various
advanced cancers [6,7]. In cases with advanced ovarian
carcinomas, platinum based chemotherapy regimens
have been found to produce higher response rates and in
some studies have produced a statistically significant sur-
vival advantages compared with drug regimens without
platinum [8,9].
Thus the two treatment options available for treating
patients with advanced ovarian tumor are either a primary
surgical cytoreduction or to start with chemotherapy hop-
ing for down staging the tumor and then go ahead with
surgery.
In this study, we report our results with these two treat-
ment modalities applied only to operable patients with-
out medical contraindications to surgery. We assessed the
patients for different variables, such as the ability to per-
form optimal debulking, rate of non-standard surgery
(Excision of more than one organ), disease free survival
and overall survival.
Patients and methods
This prospective trial included a total of 59 patients with
stage III or IV epithelial ovarian carcinomas that were eval-
uated between 1998 and 2003. Patients who were selected
for our study had advanced ovarian carcinoma and were
free from severe concomitant medical illness that could
preclude surgical interference (such as those with WHO
performance status 2, or 3). Patient characteristics are
summarized in Table 1. Patients were subjected to physi-
cal examination, serum level of CA 125 measurement,
radiological studies, and histopathological confirmation
of ovarian carcinoma. All patients were submitted to sur-
gical exploration at the Surgical Oncology Unit, Mansoura
University Hospitals. The purpose of this exploration was
to evaluate tumor resectability; to perform primary
debulking surgery when optimal cytoreduction seemed
feasible and to treat primary unresectable tumors with
neoadjuvant chemotherapy. Optimal debulking has been
variously defined, however we adopted the Gynecologic
Oncology Group definition which defines it as leaving
residual disease of less than 1 cm [10]. This strategy was
explained to the patients and informed consents were
obtained. Surgical exploration was usually done laparo-
scopically (38 cases) unless it was contraindicated, when
laparotomy was done (21 cases). Neoadjuvant chemo-
therapy was given (in 27 patients) when we considered
that optimal cytoreduction was not feasible with the
standard surgery, defined as 1) total abdominal hysterec-
tomy with bilateral salpingoophorectomy, 2) appendec-
tomy, 3) total infragastric omentectomy, 4)
peritonectomy limited to the pelvis, paracolic gutters,
anterolateral diaphragmatic area, and 5) pelvic, common
iliac, and infrarenal paraaortic lymphadenectomy. Con-
versely primary debulking surgery was performed when
we considered that optimal cytoreduction could be
achieved by the standard surgery (32 patients). However,
in a few cases non-standard surgery, meaning a single
organ resection (e.g., small intestine, colon, spleen) in the
way to achieve an optimal cytoreduction was adopted. All
patients who underwent intestinal surgery were evaluated
by a single surgeon (MH).
Chemotherapy regimens were all platinum based and
included cisplatinum 75 mg\m2 plus cyclophosphamide
600 mg\m2 (repeated every 3 weeks). This regimen was
applied to all cases of the NACT group and was applied in
all cases of the conventional group postoperatively.
The response to neoadjuvant chemotherapy was evalu-
ated after the third cycle. Clinical response to chemother-
apy was evaluated on clinical examination, serum CA 125
level, and computed tomography (CT) scan. Tumor
response was classified according to the WHO criteria.
[11]. Patients were then referred for second surgical
cytoreduction when they presented no signs of progres-
sion during chemotherapy (18 cases). The surgicopatho-
logic response to NACT was assessed at secondary surgery.
Nine patients progressed under chemotherapy and werePage 2 of 8
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cytoreduction was evaluated in terms of the blood loss
rates, and the length of intensive care unit and postopera-
tive hospital stay. A report of the peroioperative and post-
operative complications in both groups was recorded.
Survival curves since diagnosis (first surgical procedure)
were calculated according to the Kaplan Meier method,
and survival curves were compared by the log-rank test.
Results
Between April 1998 to January 2003, 59 patients pre-
sented with operable, locally advanced epithelial ovarian
carcinoma. After surgical exploration, 32 patients seemed
resectable and primary cytoreductive surgery was carried
out, and 27 patients seemed unresectable and neoadju-
vant chemotherapy was given to them. Among those
patients, 9 progressed during chemotherapy and were not
operated (Figure 1)
Patient characteristics are summarized in Table 1. When
comparing the NACT patients with the conventionally
treated patients as a group, the NACT group were statisti-
cally older (58.7 ± 4.6 years vs. 53.6 ± 4.6 years) than the
conventional group (P = 0.04)
The staging procedure was laparoscopy in 38 patients and
laparotomy in 21 patients. In the NACT group (n = 27),
the mean interval between surgical staging and the start of
chemotherapy was 13.7 days (range 5–33) days after
laparoscopy and 18.9 days (range 7–41 days) after
laparotomy (p = 0.055).
All patients then received platinum-based chemotherapy.
The median number of neoadjuvant chemotherapy cycles
Table 1: Patient characteristics
Conventional(n = 32) NACT(n = 27) p
Age 53.6 ± 9.8 58.7 ± 4.6 NS
FIGO stage
IIIc 14 (43.8%) 11 (40.7%) NS
IV 18 (56.2%) 16 (59.3%) NS
Grade
II 14 (43.8%) 12 (44.4%) NS
III 18 (56.2%) 15 (55.6%) NS
Histological type:
Serous 9 (28.1%) 7 (25.9%) NS
Mucinous 13 (40.6%) 10 (37%) NS
Undifferentiated 10 (31.3%) 10 (37%) NS
Staging procedure
Laparoscopy 21 (65.6%) 17 (62.9%) NS
Laparotomy 11 (34.4%) 10 (37.1%) NS
Treatment plan according to the results of initial explorationFigure 1
Treatment plan according to the results of initial exploration.Page 3 of 8
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response after 2 cycles and cytoreductive surgery was
done. Twenty-five patients received 3 or more cycles.
Among 27 patients of this series, 18 (66.6%) responded to
NACT according to clinical examination, serum CA 125
level and abdominopelvic CT scan. All of them showed
partial response. Conversely 9 patients showed no
response (4 cases showed a stable disease and 5 cases
showed progressive disease). Those 9 cases were not oper-
ated and referred to continue chemotherapy.
We aimed to compare the cases who were primarily oper-
ated (n = 32) and those who were operated after respond-
ing to neoadjuvant chemotherapy (n = 18) in terms of the
degree of optimal debulking and the morbidity associated
with surgical procedures.
In NACT group, optimal cytoreduction was achieved in 13
cases. Thus the optimal debulking rate was 48.1% among
the overall number of patients in this group (n = 27) and
72.2% among those who were operated (n = 18). In the
conventional group the optimal debulking rate was
(62.4%). The difference was statistically insignificant (P =
0.5). However, one must remember that 9 patients pro-
gressed while on chemotherapy and were not operated
(Table 2).
In the conventional group, non-standard surgery was per-
formed in 11 cases (34.4%), and in 4 cases (27.8%) of
NACT group (Table 3). Resection and primary anastomo-
sis of the small intestine occurred in 10 patients, partial
cystectomy was done in 3 cases, colectomy was done in 4
cases, and splenectomy in 2 cases. Multiple organ resec-
tions (MOR) occurred in two cases in the conventional
group and in one case in NACT group.
Patients in NACT group showed a significantly less blood
loss rates (p = 0.02), less ICU stay (p = 0.03), and less total
hospital stay (p = 0.05). There was no difference between
perioperative morbidity and mortality in the two patient
groups (Table 4). Complications were more in the cases
that underwent intestinal surgery (3 cases of wound infec-
tion, 6 cases of fever, and 3 cases of DVT).
On assessment of the survival we compared the whole
number of both groups i.e., we added the 9 patients who
were not surgically operated in NACT group. The median
overall survival time was 28 months in the conventional
group and 25 month in the NACT group with an insignif-
icant P value (P = 0.5) (Figure 2). The median disease free
survival was 19 months in the conventional group and 22
months in the NACT group with an insignificant P value
(P = 0.4) (Figure 3)
In multivariate analysis of both the conventional group
and NACT group, the overall survival was not significantly
affected by any of the study parameters (pathologic type,
grade, stage, degree of optimal debulking). In the conven-
tional group, the disease free survival was significantly
affected with the degree of optimal cytoreduction only (P
= 0.001) (Figure 4). In the NACT group the disease free
survival was significantly affected by the tumor type (P =
0.02) and the degree of optimal debulking (P = 0.01).
Table 2: Degree of debulking in the conventional group and the 





Optimum cytoreduction 20(62.5%) 13(72.2%)
Suboptimal cytoreduction 12(37.5%0 5(27.8%)








Number of patients 11 (34.4%) 4 (22.2%) NS
Organs resected




Overall survival in NACT and conventional groupsFigure 2
Overall survival in NACT and conventional groups.Page 4 of 8
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The clinical basis of aggressive cytoreductive surgery in the
initial management of ovarian cancer is the significantly
improved survival gained by those patients in whom opti-
mal cytoreductive surgery was accomplished [12,13]. The
presence of residual disease after surgery is one of the
most adverse prognostic factors for survival. Therefore,
although the definition of optimal cytoreduction has
been modified over the last two decades, it is generally
agreed that every attempt should be made to surgically
resect as much disease as safely possible [4].
The value of debulking after induction chemotherapy has
been largely debated in the last decades. Recently several
investigators introduced the concept of interval debulking
surgery meaning a surgical procedure with debulking
intent foreword and followed by cytoreductive chemo-
therapy [14,15]. Based on the GOG 152 data, interval
debulking surgery does not seem to be indicated in
patients who underwent primarily a maximal surgical
effort by a gynecological oncologist [15].
In a population of patients with advanced ovarian carci-
noma who deemed unresectable by surgical exploration,
neoadjuvant chemotherapy helped to select patients for
feasible and relatively less aggressive interval debulking.
Patients who did not respond or progressed under chem-
otherapy were spared surgery [16].
An issue of importance is which criteria should be used to
define the respectability of the tumor and consequently
the selection of which patients might benefit from NACT
approach. Imaging (computed tomography scan) based
criteria have been developed by different authors [17,18].
Nelson et al [17] showed that the predictive value of a pos-
itive test (CT scan demonstrating non respectability) was
only 67%. Bristow et al developed a predictive index that
was able to correctly predict surgical outcome (optimal <
1 cm versus suboptimal residual disease status) [19]. The
specificity or the ability to identify patients undergoing
optimal debulking was 80%. The authors agree with Ans-
quer et al [8] and Vergote et al [14] in that a laparoscopy
and in certain situations exploratory laparotomy provides
certain advantages as a selection tool. It allows for making
Disease free survival in NACT and conventional groupsFigure 3
Disease free survival in NACT and conventional groups.









Mean 190 150 NS
range 70–350 90–270
Blood loss rates (cc)
Mean 735 420 0.02
Range 50–5000 50–3000
ICU stay (days)
Mean 4.4 1.7 0.03
Range 1–9 1–5
Hospital stay (days)
Mean 15.9 10.5 0.05
Range 6–49 4–31
Wound infection 2 2 NS
Fever > 38.5°C > 3 d 7 1 NS
Atelectasis 1 1 NS
Pleural effusion 2 0 NS
DVT 3 1 NS
Disease free survival in both groups according to the degree of debulkingFigure 4
Disease free survival in both groups according to the degree 
of debulking.Page 5 of 8
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extent of the disease. At the same time it identifies patients
who can be optimally debulked, thus not denying the pos-
sible benefit of such a procedure. The issue of port site
implantation in this patient group can probably be
addressed by proper technique (Closure of the perito-
neum and excision of trocar port site at the definitive sur-
gery) and immediate (< 1 week) start of chemotherapy
[19]. In this study we performed laparoscopy as a selec-
tion tool in most patients unless it was contraindicated
when a laparotomy was done. The limits of standard
debulking surgery that were found at exploration were
extensive bowel involvement, large involvement of the
peritoneum located in the upper abdomen particularly in
the dorsal diaphragmatic area, and liver metastasis. These
cases were referred for neoadjuvant chemotherapy. Initia-
tion of chemotherapy was significantly delayed in the
laparotomy group than the laparoscopy group. No case
presented with port site recurrence in the laparoscopy
patients.
Chemotherapy was platinum based. The number of pre-
operative cycles ranged from 2–6. Most patients were
explored after 3 cycles. It is noteworthy to mention that
three patients who were explored after 5–6 cycles tended
more frequently to present no microscopic disease.
Indeed the optimal number of chemotherapy cycles to be
given before planned surgery is still a major, unresolved
issue. In previous published studies the number of
preoperative chemotherapy cycles ranged from 2–10 [20-
22]. It seems that the chance of achieving an optimal
debulking increases in responding patients with the num-
bers of cycles before surgery [23]. This potential advantage
has to be balanced against the risk of emergence/ selection
of drug resistant cell clones and cumulative drug toxicity
associated with the increased number of chemotherapy
cycles [20].
Eighteen patients of NACT group had a clinical response.
Optimal cytoreduction rate was 48.1% among the overall
number of patients in this group (n = 27) and 72.2%
among those who were operated (n = 18). This correlates
with previous reports of Jacob et al [12] who reported
optimal cytoreduction in 77 % of patients and Surwit et al
[24] who reported 55% of cytoreduction less than 1 cm.
We believe that the benefit of neoadjuvant chemotherapy
does not lie in its ability to obtain larger percentage of
optimal cytoreduction because the increased and the
more widespread use of newer technologies as ultrasonic
aspirator, argon beam coagulator and ultra radical surgical
procedures could increase the fraction of patients who are
optimally debulked upfront but at the likely cost of
increase morbidity [24].
The value of neoadjuvant chemotherapy is to obtain opti-
mum cytoreduction by means of less aggressive surgery. In
our study, debulking surgery in NACT group was less
aggressive than in the conventional group with less blood
loss rates, shorter intensive care stay and shorter postoper-
ative hospitalization. These finding are consistent with the
data of Schwartz et al [23] who reported that the aggres-
siveness of debulking surgery seems to be decreased after
neoadjuvant chemotherapy. There was no significant
difference between perioperative morbidity and mortality
in the two patient groups.
In our study, the median overall survival time yields no
significant difference in both groups. Onnis et al [25]
described 88 patients treated with NACT compared with
248 patients treated with upfront surgery followed by
chemotherapy. The overall survival was not improved. In
an analysis by Surwit et al, the median survival of 29
patients who underwent primary chemotherapy was 22
months, which the author said was similar to that of
patients who undergo primary surgery [24]. Schwartz et al
[21] reported on 59 patients treated with NACT of whom
41 were eventually operated compared with a control
group of conventionally treated patients, the patients
receiving NACT were significantly older and had a poor
performance status but still obtained a similar survival.
Vergote et al [14] reported that NACT resulted in survival
rates in selected patients with advanced ovarian cancer
that were comparable to those associated with primary
cytoreductive surgery.
Conversely, Kuhn et al [26], Rose et al (GOG 152) [15],
and Muggia et al (GOG 158) [27] reported prolonged sur-
vival times and significantly better median survival in
NACT group than the conventionally treated patients.
This controversy might be attributed to different patient
characteristics and different treatment modalities.
In our study, there was no significant difference in the
median disease free survival between both groups. Our
results are similar to those of Kayikcioglu et al [28] who
reported a disease free survival of 16.03 (0–84 months,
median= 12 months) in 158 patients with advanced
ovarian carcinoma treated by conventional surgery. In
145 patients who received NACT, he reported a disease
free survival of 13.9 ± 10.12 months (0–48 median 13.9
months).
Conclusion
Primary cytoreductive surgery is still the gold standard in
the treatment of ovarian carcinoma [29]. Neoadjuvant
chemotherapy for advanced unresectable ovarian carci-
noma lead to the selection of a group of patients sensitive
to chemotherapy, in whom secondary cytoreductive sur-
gery can be achieved in a less aggressive manner. AlsoPage 6 of 8
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patient with a very poor prognosis either because of pro-
gressive disease or because of primary chemoresisetence.
These findings must be confirmed by a larger prospective
study. A large randomized trial evaluating the efficacy and
morbidity of primary surgery versus neoadjuvant chemo-
therapy followed by interval debulking surgery is
ongoing.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
MAFH: obtained full data about the patients, applied the
study design, performed surgical interference to the
patients, searched literature and drafted the manuscript,
RAFH: shared in the study design, performed statistical
work and helped to draft the manuscript and edited the
final version.
MAE: obtained patient consent and shared in surgical
interference to the patients.
AES,: shared in surgical interference to the patients and in
collecting their data.
MRE: shared in surgical interference to the patients and in
collecting their data
ME shared in surgical interference to the patients and in
collecting their data,
AAFH,: gave the patients chemotherapy protocol and fol-
lowed them up.
Funding
This work was supported by an internal funding from the
Oncology Center, Mansoura University, Mansoura, Egypt.
Acknowledgements
The authors thank Prof Dr. Mohamed El Maadawy and Prof Dr. Adel 
Denewar for helpful comments.
References
1. Randall TC, Rubin SC: Cytoreductive surgery for ovarian
cancer.  Surg Clin North Am 2001, 81:871-876.
2. NIH consensus development panel: Ovarian cancer screening,
treatment and follow up.  JAMA 1995, 273:491-497.
3. Griffith CT, Parker LM, Lee S, Finkler NJ: The effect of residual
mass size on response to chemotherapy after surgical
cytoreduction for advanced ovarian cancer: long term
results.  Int J Gynacol Cancer 2002, 12:323-331.
4. Eisenkop SM, Spiretos NM, Montag TW, Nalick RH, Wang H: The
impact subspecialty training on the management of
advanced ovarian cancer.  Gynacol Oncol 1992, 46:203-209.
5. Frei E: Clinical cancer research, an embattled species.  Cancer
1982, 50:1979-1992.
6. Van der Woude HJ, Bloem JL, Verstrate KL: Osteosarcoma and
Ewing sarcoma after neoadjuvant chemotherapy: value of
dynamic MR imaging in detecting viable tumor before
surgery.  Am J Roentgenol 1995, 165:593-598.
7. Bellaton E, Bertozzi AI, Behar C, Chastagner P, Brisse H, Sainte-Rose
C, Doz F, Desjardins L: Neoadjuvant chemotherapy for exten-
sive Unilateral retinoblastoma.  Br J Ophalmol 2003, 87:327-329.
8. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P,
Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne
D, Querleu D, Dargent D: Neoadjuvant chemotherapy for
unresectable ovarian carcinoma.  Cancer 2001, 91:2329-2334.
9. Deraco M, Raspagliesi F, Kusamura S: Management of peritoneal
surface component of ovarian cancer.  Surg Oncol Clin N Am
2003, 12:561-583.
10. Gallo A, Frigerio L: Neoadjuvant chemotherapy and surgical
considerations in ovarian cancer.  Curr Opin Obstet Gynacol 2003,
1:25-31.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results
of cancer treatment.  Cancer 1981, 47:207-214.
12. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Whar-
ton JT: Neoadjuvant chemotherapy and interval debulking for
advanced epithelial ovarian cancer.  Gynecol Oncol 1991,
42:146-150.
13. Hoskins WJ: Surgical staging and cytoreductive surgery of epi-
thelial ovarian Cancer.  Cancer 1993, 71(4 Suppl):1534-1540.
14. Vergote I, de Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van
Dam P: Interval debulking surgery: an alternative for primary
surgical debulking?  Semin Surg Oncol 2000, 19:49-53.
15. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin
SC, Moore DH: Phase III randomized study of interval second-
ary cytoreduction in patients with advanced stage ovarian
carcinoma with suboptimal residual disease. A Gynecology
Oncology Group study.  Proc ASCO 2002, 21:201a [http://
www.asco.org/ac/1,1003,_12-002643-00_18-0016-00_19-
00802,00.asp]. [Abstract 802] [Last accessed August 27, 2005]
16. Cannistra SA: Cancer of the ovary.  N Engl J Med 1993,
329:1550-1559.
17. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdomi-
nopelvic Computed tomography prediction of optimal
cytoreduction in epithelial ovarian carcinoma.  J Clin Oncol
1993, 11:166-172.
18. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC: Ovarian
carcinoma: Value of CT in predicting success of debulking
surgery.  Am J Roentgenol 1995, 165:875-878.
19. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble
EL, Montz FJ: A model for predicting surgical outcome in
patients with advanced ovarian carcinoma using computed
tomography.  Cancer 2000, 89:1532-1540.
20. Baekelandt M: The potential role of neoadjuvant chemother-
apy in advanced ovarian caner.  Int J Gynecol Cancer 2003,
13(suppl 2):163-168.
21. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP: Neo-
adjuvant chemotherapy for advanced ovarian cancer: long
term survival.  Gynecol Oncol 1999, 72:93-99.
22. Chambers JT, Chambers SK, Voynick IM, Schwartz PE: Neoadjuvant
chemotherapy in a stage X ovarian carcinoma.  Gynecol Oncol
1990, 37:327-331.
23. Schwartz PE: Neoadjuvent chemotherapy for the manage-
ment of ovarian cancer.  Best Pract Res Clin Obstet Gynaecol 2002,
16:585-596.
24. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D:
Neoadjuvant chemotherapy for advanced ovarian cancer.  Int
J Gynaecol Cancer 1996, 6:356-361.
25. Onnis A, Marchetti M, Padovan P, Castellan L: Neoadjuvant chem-
otherapy in advanced ovarian cancer.  Eur J Gyncol Oncol 1996,
17:393-396.
26. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hun-
delshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemo-
therapy followed by tumor debulking prolongs survival for
patients with poor prognosis in International Federation of
Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Cancer 2001, 92:2585-2591.
27. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL,
Alvarez RD, Kucera PR, Small JM: Phase III randomized study of
cisplatin versus paclitaxel versus cisplatin and paclitaxel in
patients with suboptimal stage III or IV ovarian cancer: aPage 7 of 8
(page number not for citation purposes)
World Journal of Surgical Oncology 2005, 3:57 http://www.wjso.com/content/3/1/57Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
gynecologic oncology group study.  J Clin Oncol 2000,
18:106-115.
28. Kayikçiog Lu F, Köse MF, Boran N, Çalikan E, Tulunay G: Neoadju-
vant chemotherapy or primary surgery in advanced epithe-
lial ovarian carcinoma.  Int J Gynecol Cancer 2001, 11:466-470.
29. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin
SC, Moore DH, Small JM, Gynecologic Oncology Group: Secondary
surgical cytoreduction for advanced ovarian carcinoma.  N
Eng J Med 2004, 351:2489-2497.Page 8 of 8
(page number not for citation purposes)
